drug
Lead Candidate
Preclinicalupdated 6mo agoby MaavRx Ltd
Preclinicalcommunity read0 votes
indications
indications
Parkinson's Disease
all catalysts(0)
nothing on the calendar yet
News(10)
- AstraZeneca, Calidi, Tempest make significant workforce cutsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Marrow Therapeutics debuts with $173M to tackle blood disorders in vivoMarrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.biospace · 1d ago
- Kyntra axes mid-stage ADC, adding to years of stumblesBeleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the last few years, and now the biotech is cutting a clinical antibody-drug con…fiercebiotech · 1d ago
- Lilly signs $5.9B deal with Stipple to unlock oncology targetsEli Lilly has struck a $5.9 billion deal to partner with Stipple Bio on oncology drug candidates that more precisely target tumor cells.fiercebiotech · 1d ago
- Sellas marks 9-month survival benefit in late-stage leukemia vaccine studySellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.fiercebiotech · 2d ago
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 2d ago
- J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trialBlackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setba…biospace · 2d ago
- Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer workEli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.biospace · 2d ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 2d ago
- Marrow extracts $120M series B to advance preclinical blood disease therapyA new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…fiercebiotech · 5d ago
Data sources
last refreshed 8h ago
Found something off?
comments(0)
5-min edit window · permanent after that